The Manila Times

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-gra…

If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with ...